Neuroscience Clinical Trials
The purpose of Neuroscience Research at Powers Health is to encourage and actively support advancements that aim to reduce the morbidity and mortality related to neurological disorders in Northwest Indiana through participation in clinical research initiatives.
Please note: The information on this site does not replace that of your physician. Always contact your doctor before making a change in your treatment. For additional information regarding the contents of this site, please call Powers Health Neuroscience Research at 219-703-1010.
The benefits of clinical trials come from observation. Investigators work to develop new ideas, concepts and methods for the advancement of current practices and improve patient outcomes. Clinical trials are geared toward the patient’s benefit with the idea that the patient will always receive the most current medication or procedure.
Clinical trials measure the effectiveness of new medical therapies, such as a drug or a device. Each study is specific to a therapy that finds better ways to prevent, screen, diagnose or treat a disease. Clinical trials may also compare a new treatment to a treatment that is already available.
Active Stroke Trials
Librexia Stroke: The purpose of this Study is to Demonstrate the Efficacy and Safety of
Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention After an Acute
Ischemic Stroke or High-Risk Transient Ischemic Attack
National Clinical Trial #: NCT05702034
Timekeeper: This study will evaluate the safety and efficacy of the drug Tenecteplase, a clot Buster, also known as Tissue Plasminogen Activator (tPA)
Revive: The purpose of this Study is to Investigate the Efficacy and Safety of Redasemtide
compared with placebo in adult Participants with Acute Ischemic Stroke who are not
eligible for Tissue Plasminogen Activator or Thrombectomy.
National Clinical Trial #: NCT05953480
ReMEDy2: The purpose of this trial is to evaluate the efficacy and safety of the drug
DM199, compared with Placebo in Stroke patients within 24 hours of Stroke Onset.
National Clinical Trial #: NCT05065216
PICASSO Trial: The primary objective of this trial is to establish the efficacy of intra-arterial (IA)
mechanical thrombectomy (MT) with extracranial proximal carotid artery acute
stenting versus non-stenting approaches in patients with acute ischemic stroke
(AIS) from intracranial vessel occlusion (IVO) in the anterior circulation and have a
proximal carotid occlusive disease (occlusion or severe stenosis) within 24 hours
of symptom onset.
National Clinical Trial #: NCT05611242
Completed Stroke Trials
CLEAR: This trial assesses the efficacy of a new device, the NeVa Stent Retriever, for clot removal in Stroke Patients.
TESLA: The purpose of the trial is to determine the effect of a clot removal procedure in addition to standard of care in Stroke Patients.
TIMELESS: The purpose of this trial is to evaluate the efficacy and safety of the drug Tenectaplase, compared with Placebo, in Stroke patients in an extended treatment window of 4.5 hours to 24 hours of Stroke Onset.
Current trials offered at Powers Health are for acute stroke patients. All stroke-alert patients are screened, and if they qualify, they will be approached by the Principal Investigator or other delegated Research staff to participate in a trial.
Patients who desire to participate in clinical trials will be given a document called an informed consent that describes the information about the treatment you will receive along with the risks and benefits. Patients will be given ample time to go over the document and may direct questions to the study doctor and/or the study staff. If the patient decides to participate in the study, their signature will be obtained before starting any study specific treatment.
Anyone who participates in a clinical trial has the right to leave the study at any time. If a patient decides not to participate in the trial, they will no longer be in the study and the study treatment will be discontinued. However, the standard of care treatment will continue.
If there is a specific drug or device used in the clinical trial, the patient will not be charged for the drug or device. If specific testing is requested for the trial that is not considered standard of care, the patient will not be charged for that testing. All other charges are billed to the patient and/or insurance.
Depending on the nature of the study, trials can run from 3 months up to 42 months or longer.
Support for neuroscience clinical trials at Powers Health removes barriers to community access, enabling treatment close to home. Funding is also used to educate the public and spread awareness on the prevention of stroke and other brain diseases.
Learn more about how to support neuroscience clinical trials here.